Zolgensma denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for zolgensma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare May Deny Zolgensma Under Step Therapy

Step therapy (also called "fail-first") denials require a patient to try one or more other treatments before the insurer will authorize the requested medication. For Zolgensma (onasemnogene abeparvovec), a step-therapy denial from UnitedHealthcare typically means the plan requires documented use of — and inadequate response to — other approved SMA therapies before authorizing this gene therapy.

This is one of the most frequently contested denial types for Zolgensma, and there are strong grounds for appeal. Zolgensma works through a distinct mechanism (gene replacement) that other SMA therapies do not replicate. More critically, the therapy's established benefit is time-sensitive: disease progression in SMA can cause irreversible motor neuron loss, and delaying treatment to complete a step-therapy sequence can foreclose the window in which Zolgensma is most effective. Many states have enacted step-therapy override laws that require payers to waive step requirements when delay would cause irreversible harm or when the step drug is contraindicated or clinically inappropriate.

## Your Appeal Rights

• Step-therapy exception request: Most plans have a formal exception process. Your physician must document why the required step drug is clinically inappropriate, contraindicated, or why the delay would cause irreversible harm. Submit this as a written exception request before or alongside the appeal.
• Internal appeal (ERISA §503): File a written internal appeal within the deadline on the denial letter. You are entitled to a full-and-fair review and access to all clinical criteria the plan applied.
• External review (ACA §2719): After an adverse internal decision, independent external review is available within a four-month window. For rapidly progressing disease, expedited external review (72-hour turnaround) should be requested simultaneously.
• State law: If your plan is state-regulated (not ERISA self-funded), check whether your state has a step-therapy override statute; many states require a waiver when delay poses irreversible harm.

## Documentation to Gather

1. Genetic diagnosis — laboratory report confirming SMA with SMN1 status and SMN2 copy number. 2. Disease type, staging, and urgency — neurologist notes documenting SMA type, age at onset, current functional status, and a clinical statement about the time-sensitive nature of treatment. 3. Prior treatment history — dates, outcomes, and clinical response (or clinical rationale for bypassing) each step drug listed in the UHC policy. 4. Clinical urgency statement — a prescriber letter explicitly addressing why completing the step-therapy sequence would result in irreversible harm or clinically unacceptable delay for this specific patient. 5. Applicable guideline reference — cite the relevant professional society guidance (e.g., from the Child Neurology Society or SMA expert panels) supporting early or first-line gene therapy in appropriate candidates. 6. Prescriber medical-necessity letter — tying together the genetic, clinical, and urgency rationale.

## Criteria-Mapping Structure

Obtain UHC's step-therapy policy for Zolgensma and the FDA-approved prescribing label. Map each step requirement:

| Step Requirement | Chart Evidence or Exception Basis | |---|---| | Trial of step drug 1 (per UHC policy) | Treatment log with dates, OR clinical rationale for exception | | Trial of step drug 2 (if applicable) | Treatment log with dates, OR clinical rationale for exception | | Documented inadequate response or contraindication | Prescriber note with date | | Urgency / irreversible-harm documentation | Neurologist clinical statement |

The exception letter should be written by the treating neurologist and should directly address why waiting constitutes irreversible harm — this is often the single most persuasive document in a step-therapy appeal for Zolgensma.